Simcere Pharmaceutical Group Ltd
HKEX:2096
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.03
7.47
|
Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Simcere Pharmaceutical Group Ltd
Intangible Assets
Simcere Pharmaceutical Group Ltd
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Simcere Pharmaceutical Group Ltd
HKEX:2096
|
Intangible Assets
ÂĄ715.8m
|
CAGR 3-Years
110%
|
CAGR 5-Years
71%
|
CAGR 10-Years
N/A
|
||
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Intangible Assets
ÂĄ177.4m
|
CAGR 3-Years
162%
|
CAGR 5-Years
76%
|
CAGR 10-Years
N/A
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Intangible Assets
ÂĄ279.1m
|
CAGR 3-Years
6%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
||
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Intangible Assets
ÂĄ4.2B
|
CAGR 3-Years
112%
|
CAGR 5-Years
64%
|
CAGR 10-Years
36%
|
||
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Intangible Assets
ÂĄ593.5m
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
||
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Intangible Assets
ÂĄ28m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Simcere Pharmaceutical Group Ltd
Glance View
Simcere Pharmaceutical Group Ltd., established in China, navigates the complexities of the pharmaceutical industry with a focus on innovation and accessibility. Emerging as a dynamic player, Simcere embraces a strategy that marries research-driven innovation with pragmatic commercial practices. The company operates a diversified portfolio, prominently featuring pharmaceuticals dedicated to oncology, cardiovascular diseases, and the central nervous system. By maintaining a robust pipeline of new drug candidates while leveraging its existing catalog, Simcere adeptly navigates the challenges of the pharma landscape. Their dedication to research and development is evident, with substantial investment channeled towards creating proprietary medicines that aim to address unmet medical needs and improve patient outcomes. The path to profitability for Simcere hinges on its dual strategy of developing novel therapeutics and forming strategic partnerships. Simcere not only invests heavily in its proprietary R&D but also engages in collaborations with global pharmaceutical enterprises, thus expanding its reach and influence in the global market. The company adeptly manages a sophisticated supply chain to ensure its products are both widely distributed and affordable, adhering to high standards of regulatory compliance in various metropolises. This operational efficiency, coupled with the strategic alliances, allows Simcere to capture significant market share, driving top-line growth and reinforcing its reputation as an innovative leader in the pharmaceutical industry.
See Also
What is Simcere Pharmaceutical Group Ltd's Intangible Assets?
Intangible Assets
715.8m
CNY
Based on the financial report for Dec 31, 2023, Simcere Pharmaceutical Group Ltd's Intangible Assets amounts to 715.8m CNY.
What is Simcere Pharmaceutical Group Ltd's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
71%
Over the last year, the Intangible Assets growth was 88%. The average annual Intangible Assets growth rates for Simcere Pharmaceutical Group Ltd have been 110% over the past three years , 71% over the past five years .